Catalent increased sterile fill-finish manufacturing capacity at its Research Triangle Park facility in NC
5 June 2012 | By Catalent Pharma Solutions
Completion of a newly renovated aseptic fill-finish manufacturing facility announced...
List view / Grid view
News
Merck receives complete response letter from U.S. FDA for investigational medicine ridaforolimusr
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
Abbott announces initiation of Phase 3 study of Elagolix in patients with endometriosis
5 June 2012 | By Abbott
Abbott have announced the initiation of a pivotal Phase 3 clinical trial...
Abbott introduces Ensure Clear™ to help adults fill dietary gap
5 June 2012 | By Abbott
One in three adults doesn’t obtain all of the daily nutrients they need to support optimal health...
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
Gerresheimer at CPhI China
4 June 2012 | By Gerresheimer
Gerresheimer will be showcasing innovative solutions for the pharma industry at CPHI China, which takes place in Shanghai from June 26 to 28...
GSK presents positive results for investigational BRAF and MEK inhibitors dabrafenib and trametinib at ASCO
4 June 2012 | By
Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints...
Phase III study: patients with most common type of lung cancer lived longer with ALIMTA-based continuation maintenance therapy
4 June 2012 | By Eli Lilly and Company
Overall survival data from PARAMOUNT study submitted to FDA...
Lung cancer study showed encouraging results for ALIMTA-based regimens and full-dose radiation
4 June 2012 | By Eli Lilly and Company
Eli Lilly and Company announced results of a Phase II trial evaluating ALIMTA®...
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
4 June 2012 | By Boehringer Ingelheim
LUX-Lung 3 results highlighted at the official ASCO Press Conference...
resDNASEQ® E. coli Residual DNA Quantitation System
1 June 2012 | By Life Technologies
Integrated sample preparation and real-time PCR assay for the quantitation of E. coli host cell DNA...
Beat In-Albon new COO of the life science ingredients sector
Starting on 1 June 2012, Beat In-Albon will join Lonza as COO of the Life Science Ingredients Sector and become a member of the Management Committee, replacing Harry Boot. Beat In-Albon brings broad industry experience to his role, having worked for Lonza already from 1983-2006, where he was Head of…
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS
1 June 2012 | By GlaxoSmithKline
GSK has clearance under the U.S. anti-trust laws to acquire HGS...
Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects
1 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new partnership with ammado...
Catalent enters agreement to sell its U.S. commercial packaging operations
31 May 2012 | By Catalent Pharma Solutions
Catalent signed a definitive agreement to sell its U.S. commercial packaging operations based in Philadelphia, PA and Woodstock, IL...
